Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Fertilo is an engineered line of ovarian support cells that aid egg maturation.”In the company’s words, NCT06858111 on ClinicalTrials.gov
- Tested for
- In Vitro Maturation of Oocytes
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the safety and efficacy of using Fertilo for In vitro maturation (IVM) in participants 18-35 years of age. The main question it aims to answer is whether the use of Fertilo is superior to using Medicult IVM for In vitro maturation. Researchers will compare the number of ongoing pregnancies at 12 weeks gestation for participants in each arm. * Arm 1 participants will have all cumulus oocyte complexes (COCs), or eggs surrounded by helper cells, cultured in Fertilo for 30 hours. * Arm 2 participants will have all cumulus oocyte complexes (COCs),…”In the company’s words, NCT06858111 on ClinicalTrials.gov
Other drugs for In Vitro Maturation of Oocytes
- Follitropin alfa/lutropin alfaMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Phase 3
- PKB171Prokrea BCN, S.L. · Phase 2/3
- HMGGranata Bio Corporation · Phase 3
- MibavademabRegeneron · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
- QL1012DQilu Pharmaceutical · Phase 1
Coming up1
- May 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | May 2027 | Fertilo In Vitro Research Study and Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026